Skip to main content

Table 5 Adverse events

From: Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy

Variable

CCRT group (n = 49)

IC plus RT group (n = 49)

IC plus CCRT group (n = 49)

P value*

Total Grade 3–4 acute adverse events

16 (32.7 %)

19 (38.8 %)

20 (40.8 %)

0.685

Hematologic

 Leukopenia

4 (8.2 %)

10 (20.4 %)

11 (22.4 %)

0.126

 Neutropenia

3 (6.1 %)

9 (18.4 %)

9 (18.4 %)

0.135

 Anemia

0 (0 %)

1 (2 %)

1 (2 %)

1.000

 Thrombocytopenia

2 (4.1 %)

2 (4.1 %)

2 (4.1 %)

1.000

Non–hematologic

 Dermatitis

1 (2 %)

2 (4.1 %)

2 (4.1 %)

1.000

 Mucositis

11 (22.4 %)

7 (14.3 %)

12 (24.5 %)

0.415

 Dysphagia

1 (2 %)

0 (0 %)

1 (2 %)

1.000

 Nausea/vomiting

2 (4.1 %)

2 (4.1 %)

3 (6.1 %)

1.000

 Dry mouth

0 (0 %)

0 (0 %)

0 (0 %)

-

 Ototoxicity

0 (0 %)

0 (0 %)

0 (0 %)

-

 Hepatoxicity

0 (0 %)

3 (6.1 %)

1 (2 %)

0.324

 Nephrotoxicity

0 (0 %)

0 (0 %)

0 (0 %)

-

 Neurotoxicity

0 (0 %)

0 (0 %)

0 (0 %)

-

  1. Abbreviations: IC induction chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy
  2. *P-values were calculated using the Chi-square test (or Fisher’s exact test, if the expected number was less than five in at least 25 % of the cells)